Security Snapshot

BICYCLE THERAPEUTICS PLC - American Depositary Shares, each representing one ordinary share, nominal value 0.01 euro per share (BCYC) Institutional Ownership

CUSIP: 088786108

13F Institutional Holders and Ownership History from Q2 2019 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

97

Shares (Excl. Options)

37,459,664

Price

$4.64

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
-1,713,415
Value change
-$22,803,169
Number of holders
97
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
50,340,741
SEC-reported price per share
$4.73
Insider filing price
$4.73
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • BCYC - BICYCLE THERAPEUTICS PLC - American Depositary Shares, each representing one ordinary share, nominal value 0.01 euro per share is tracked under CUSIP 088786108.
  • 97 institutions reported positions in Q1 2026.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 108 to 97 between Q4 2025 and Q1 2026.
  • SEC-reported value moved from $277,661,671 to $173,586,582.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 97 institutions filings for Q1 2026.

Open SEC evidence

Security key

088786108

Latest holder period

Q1 2026

13F holders

97

13D/G owners

6

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
6
Security
BCYC
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Forbion Growth Opportunities Fund II Cooperatief U.A. 7.3% $28,343,629 3,452,330 Forbion Growth Opportunities Fund II Cooperatief U.A. 21 Nov 2024
ARMISTICE CAPITAL, LLC 6.8% +4.5% $16,922,040 +$806,760 3,398,000 +5% Armistice Capital, LLC 31 Mar 2026
Long Focus Capital Management, LLC 6.6% $16,487,221 3,310,687 LONG FOCUS CAPITAL MANAGEMENT, LLC 31 Mar 2026
Point72 Asset Management, L.P. 3.9% -49% $14,882,536 -$15,032,008 1,860,317 -50% Point72 Asset Management, L.P. 30 Jun 2025
Invus Global Management, LLC 3.1% -53% $7,773,192 -$7,909,072 1,560,882 -50% Raymond Debbane 31 Mar 2026
Deep Track Capital, LP 2.4% -54% $9,625,952 -$12,943,416 1,203,244 -57% Deep Track Capital, LP 30 Jun 2025

As of 31 Mar 2026, 97 institutional investors reported holding 37,459,664 shares of BICYCLE THERAPEUTICS PLC - American Depositary Shares, each representing one ordinary share, nominal value 0.01 euro per share (BCYC). This represents 74% of the company’s total 50,340,741 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
69%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BAKER BROS. ADVISORS LP 22% 10,885,357 0% 0.29% $50,508,056
FCPM III SERVICES B.V. 6.9% 3,468,430 0% 2.2% $16,093,515
ARMISTICE CAPITAL, LLC 6.7% 3,398,000 +5% 0.52% $15,766,720
Long Focus Capital Management, LLC 6.6% 3,310,687 +103% 0.68% $15,361,588
ACADIAN ASSET MANAGEMENT LLC 3.9% 1,968,025 +18% 0.01% $9,111,000
Siren, L.L.C. 3.1% 1,560,882 -22% 0.2% $7,242,492
GSK plc 3% 1,529,561 0% 1.2% $7,097,163
PRINCIPAL FINANCIAL GROUP INC 2.3% 1,174,625 +2.3% 0% $5,450,260
PRICE T ROWE ASSOCIATES INC /MD/ 2% 1,028,243 -12% 0% $4,772,000
RENAISSANCE TECHNOLOGIES LLC 1.9% 979,300 +73% 0.01% $4,543,952
MORGAN STANLEY 1.2% 618,327 +33% 0% $2,869,038
SCHRODER INVESTMENT MANAGEMENT GROUP 1.2% 615,833 +5.3% 0% $2,672,715
DIADEMA PARTNERS LP 0.95% 476,424 0.99% $2,210,607
Birchview Capital, LP 0.92% 463,599 +0.19% 1.2% $2,151,099
SILVERCREST ASSET MANAGEMENT GROUP LLC 0.85% 428,684 -10% 0.01% $1,989,094
MARSHALL WACE, LLP 0.75% 377,335 +873% 0% $1,750,834
CITADEL ADVISORS LLC 0.75% 377,085 +39% 0% $1,749,674
Qube Research & Technologies Ltd 0.61% 308,617 0% $1,431,983
MILLENNIUM MANAGEMENT LLC 0.56% 283,986 -13% 0% $1,317,695
BlackRock, Inc. 0.55% 278,992 -16% 0% $1,294,523
MOORE CAPITAL MANAGEMENT, LP 0.55% 275,000 0% 0.05% $1,276,000
Rangeley Capital, LLC 0.46% 232,260 +76% 1.2% $1,077,686
JANE STREET GROUP, LLC 0.43% 218,115 +245% 0% $1,012,053
Palo Alto Investors LP 0.4% 201,890 -8.7% 0.14% $936,770
Eversept Partners, LP 0.38% 190,715 +6.6% 0.06% $884,918

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
28
Latest
Q1 2026
Rows shown
1-25 of 28
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 37,459,664 $173,586,582 -$22,803,169 $4.64 97
2025 Q4 39,173,179 $277,661,671 +$3,442,632 $7.08 108
2025 Q3 36,906,185 $285,619,779 -$29,768,237 $7.74 99
2025 Q2 41,200,406 $286,338,478 -$7,404,258 $6.95 110
2025 Q1 41,735,285 $354,350,748 -$8,366,393 $8.49 95
2024 Q4 41,890,221 $586,472,317 -$21,543,705 $14.00 96
2024 Q3 40,439,351 $915,266,321 +$21,080,974 $22.63 104
2024 Q2 39,722,044 $803,959,492 +$167,237,644 $20.24 105
2024 Q1 30,475,266 $758,677,656 +$6,974,793 $24.90 93
2023 Q4 31,374,408 $567,252,558 -$28,664,876 $18.08 98
2023 Q3 32,418,922 $651,281,538 +$165,201,151 $20.09 101
2023 Q2 24,236,173 $618,449,426 +$18,484,148 $25.52 84
2023 Q1 23,558,818 $498,895,905 -$47,151,037 $21.27 89
2022 Q4 23,577,228 $697,847,861 +$39,624,167 $29.60 87
2022 Q3 23,196,999 $539,598,338 +$13,911,506 $23.26 77
2022 Q2 22,709,672 $381,075,755 -$69,885,312 $16.78 78
2022 Q1 20,168,148 $884,247,452 -$137,175,184 $43.88 100
2021 Q4 21,550,279 $1,311,636,981 +$387,558,387 $60.87 98
2021 Q3 14,210,499 $591,072,741 +$80,484,868 $41.59 67
2021 Q2 12,412,613 $376,901,461 +$30,169,498 $30.36 53
2021 Q1 11,420,830 $341,203,000 +$123,064,104 $29.87 39
2020 Q4 7,328,435 $131,544,000 -$3,975,466 $17.95 27
2020 Q3 7,550,163 $143,830,000 +$24,085,212 $19.05 18
2020 Q2 6,287,737 $98,861,000 +$4,298,929 $15.74 15
2020 Q1 5,977,254 $81,901,000 +$1,078,206 $13.65 12
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .